MED Medartis AG

EQS-News: Medartis Holding AG | Einladung Medien- und Investorenkonferenz | Jahresergebnisse 2020

EQS Group-News: Medartis Holding AG / Schlagwort(e): Jahresergebnis
Medartis Holding AG | Einladung Medien- und Investorenkonferenz | Jahresergebnisse 2020

02.03.2021 / 10:00

Einladung / Invitation: Medartis 2020 full-year results

English - see below

Sehr geehrte Damen und Herren

Medartis Holding AG wird ihre Jahresergebnisse 2020 am 10. März 2021 um 07:00 Uhr MEZ veröffentlichen. Gerne laden wir Investoren, Finanzanalysten und Medienschaffende wie folgt ein:

Telefonkonferenz (in englischer Sprache)

Datum: Mittwoch, 10. März 2021
Zeit: 10:00 Uhr MEZ
Referenten: Christoph Brönnimann, CEO; Dominique Leutwyler, CFO

Link zur Teilnahme:

Einwahlnummern per Telefon (ab 10-15 Minuten vor Beginn der Konferenz):
Schweiz/Europa +41 (0) 58 310 50 00, GB +44 (0) 207 107 06 13, USA +1 (1) 631 570 56 13
Weitere internationale Nummern

Unterlagen zu den Jahresergebnissen 2020

Die Medienmitteilung, die Präsentation sowie der Geschäftsbericht 2020 stehen am 10. März 2021 ab 7:00 Uhr MEZ unter zur Verfügung.

# # # # #

Dear Ladies and Gentlemen

Medartis Holding AG will publish its 2020 full-year results on 10 March 2021 at 7:00 CET. We would like to invite investors, financial analysts and media representatives as follows:

Telephone conference (in English language)

Date: Wednesday, 10 March 2021
Time: 10:00 CET
Speakers: Christoph Brönnimann, CEO; Dominique Leutwyler, CFO

Participant's Link:

Participants may call the following numbers, 10-15 minutes before the conference start:
Switzerland/Europe +41 (0) 58 310 50 00, UK +44 (0) 207 107 06 13, US +1 (1) 631 570 56 13
Other international numbers see

Documents 2020 full-year results

The press release, the presentation as well as the 2020 annual report will be available on 10 March 2021 as of 7:00 CET at .

Freundliche Grüsse / Kind regards

Patrick Christ
Head Corporate Services

Phone direct: 0
Phone switchboard: 4
Fax: 2


Ende der Medienmitteilungen
Sprache: Deutsch
Unternehmen: Medartis Holding AG
Hochbergerstrasse 60E
4057 Basel
Schweiz
Telefon: 4
Fax: 0
E-Mail:
Internet:
ISIN: CH0386200239
Valorennummer: 38620023
Börsen: SIX Swiss Exchange
EQS News ID: 1172071

 
Ende der Mitteilung EQS Group News-Service

1172071  02.03.2021 

fncls.ssp?fn=show_t_gif&application_id=1172071&application_name=news&site_id=research_pool
DE
02/03/2021

Underlying

MEDMedartis AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medartis AG

Maria Vara ... (+3)
  • Maria Vara
  • Oscar Haffen Lamm
  • Valliant Campagne
IPH Innate Pharma S...
VLS VALNEVA SE ... (+6)

Suspension of coverage

From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.INNATE PHARMAINVENTIVAMEDACTAMEDARTISONWARD MEDICALVALNEVA

IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
MED MEDARTIS AG
MOVE MEDACTA GROUP
IVA INVENTIVA ADS
ONWD ONWARD OPPORTUNITIES LIMITED
05/30/25 May 30, 2025 1 EN
Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis: Operational strength and strategic outlook - Basel visit tak...

Last week, we had the opportunity to visit Medartis’ HQ in Basel, Switzerland, providing first-hand insights into the company’s surgeon-first culture, operational execution, and near-term strategic priorities—particularly in the US market following recent leadership changes. While we observed no de

05/14/25 May 14, 2025 1 EN
Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis: Solid finish to 2024 with numerous strategic plans for 2025

Medartis reported FY2024 core sales growth of 11.7% (CER), placing it at the lower end of its updated guidance range of 12–15% post-H1, with total sales reaching CHF224.8mm (CHF219.6m core). Profitability outperformed expectations, delivering a 19.0% core EBITDA margin—up 1.9PP YoY versus guidance

03/18/25 March 18, 2025 1 EN
Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis: revising expectations ahead of FY'24 earnings, PT adjusted t...

Medartis faced a volatile market in 2024, marked by a CEO transition and weaker-than-expected H1 performance in key geographies, prompting a downward revision of FY sales guidance to 12–15% CER (from 15–17%). Nonetheless, Medartis maintained its EBITDA margin guidance at ~15% CER, supported by cost

02/10/25 February 10, 2025 1 EN
Maria Vara
  • Maria Vara
MED MEDARTIS AG

Medartis: US and EMEA sales ramp up but FY guidance downgraded

In H1 2024, the company reported underlying sales growth of 13.1% (CER), with total growth including third-party manufacturing at 10.8% CER, resulting in net sales of CHF 111.5m (CHF 103.3m). The US market led with a YoY growth of 20.6%, followed by EMEA at 17.8%, while growth in APAC and LATAM was

08/20/24 August 20, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch